<DOC>
	<DOCNO>NCT00720018</DOCNO>
	<brief_summary>The primary objective compare pharmacokinetics ( PK ) profile among five NP101 patch healthy volunteer . The secondary objective evaluate safety NP101 healthy volunteer .</brief_summary>
	<brief_title>Phase I Open Label Single-Dose Study Compare Pharmacokinetics NP101 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Healthy Caucasian men woman age 18 45 . Subjects BMI 18 30 kg/m2 inclusive . Subject judge good health , base upon result medical history , physical examination , vital sign , ECG laboratory profile . Subjects clinically significant abnormal finding order qualify enrollment . Subject must negative drug screen screen Day 1 treatment . Subjects must nonsmoker , define use tobacco product 6 month screen . The subject receive medication except birth control , two week prior study entry . Subjects must consume alcoholic beverage , poppy seed , grapefruit , and/or grapefruit juice within 72 hour prior admission . Female childbearing potential must negative pregnancy test screen Day 1 treatment . In investigator 's opinion , subject must likely complete study . Subjects must able communicate effectively capable read understand English voluntarily sign IRB approve IC agreement . Subject history allergy hypersensitivity component study patch use study . Subject generalize skin irritation disease include eczema , psoriasis , melanoma , contact dermatitis acne . Subject tattoo might interfere skin irritation examination . Subject history epilepsy condition associate lowered seizure threshold . Subject history basilar hemiplegic migraine . Subject suspect confirmed cardiovascular disease contraindicate participation . Subject Raynaud 's disease . Subject history ( within 1 year ) current evidence drug alcohol abuse dependence . Subject history malignancy within past 5 year . Subject clinically significant abnormal laboratory parameter , vital sign ECG parameter . Subject SGOT/AST , SGPT/ALT , alkaline phosphatase total bilirubin â‰¥ 1.5 time upper limit normal . Subject hemoglobin ( Hgb ) level le 7.5 mmol/L . Subject hepatitis B , hepatitis C HIV positive . Subject take MAO inhibitor , preparation contain St. John 's Wort , SSRI , SNRI , TCA , triptan ergot medication , within one month prior screen . Subject unwilling discontinue use phosphodiesterase type 5 inhibitor , screen End Study . Subject administer injectable drug , except local anesthetic birth control , within 30 day prior initial study drug administration . Donation blood blood product within 8 week prior study entry . Receipt investigational drug participation clinical study within 90 day prior study . Subject require medication regular basis , exception steroidal contraceptive . Concurrent use Rx OTC medication natural medicine ( herbal ) product , exception steroidal contraceptive . Female subject pregnant , plan pregnancy study , breast feeding ; childbearing potential , use unwilling use effective form contraception study period 30 day follow dosing . Subject consider unsuitable candidate receiving sumatriptan , unsuitable reason . Subject electrically sensitive ( e.g. , prior iontophoresis adverse outcome relate current deliver device ) implantable electronic device ( e.g. , pacemaker ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>